VACCIBODY - Key Persons
Job Titles:
- Chief Business Officer
- Co - Founder
- Member of the Senior Management Team
- Co - Founder of Nykode Therapeutics
Agnete is a co-founder of Nykode Therapeutics and has served in various roles including Chief Scientific Officer from 2007-2021, leading our scientific strategy. Her previous employers include Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. Agnete holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first Vaccibody™ vaccine molecules. She received the King's Gold Medal of Merit for her Ph.D. thesis describing vaccibodies.
Job Titles:
- Board Member, Chair of Audit Committee, Member of Remuneration Committee
- Chief Investment Officer of the Life Science Investment Company Radforsk
Anders is Chief Investment Officer of the life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional in the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders also holds several chairman and non-executive director positions with Norwegian biotech companies. He has an MBE degree.
Job Titles:
- Board Member, Member of Remuneration Committee, Member of R & D Committee
Anne is an experienced executive with 30 years of experience in the life sciences industry, spanning large pharmaceutical, biotech, and specialty pharmaceutical companies. Her extensive leadership background includes CEO roles at three clinical-stage biotech businesses: Aerami Therapeutics, Synta Pharmaceuticals and Novoclem Therapeutics. This is complemented by significant experience in larger pharma, notably at Bausch Health, Sanofi, and GSK. At GSK, she held senior commercial roles at both local US and global levels and was responsible for running Sanofi's North American commercial and medical operations. Anne also serves as a non-executive director of several international companies. She holds a Bachelor of Science in Chemistry from the University of North Alabama, USA.
Job Titles:
- Board Member, Member of R & D Committee
Bernd R. Seizinger, M.D., Ph.D., serves as chair or board member of several public and private biotech companies in the U.S., Europe, including Aprea, Aptose, BioInvent, CryptoMedix, Oncolytics and Oxford BioTherapeutics. In addition, he serves on the advisory board of Pureos BioVentures (Zurich) and is senior advisor to Hadean Ventures (Stockholm and Oslo). His previous roles include CEO and Senior Executive positions at GPC Biotech, Genome Therapeutics Corporation and Bristol-Myers Squibb. Before entering the biotech and pharma industries, he was a Senior Faculty Member of Harvard Medical School/Massachusetts General Hospital and Princeton University. He is a medical doctor and holds a Ph.D. in neurobiology.
Job Titles:
- Board Member, Member of R & D Committee
- Senior Vice President, Head of Clinical Development
Birgitte currently serves as Senior Vice President, Head of Clinical Development and Medical Affairs of Ascendis Pharma A/S (Nasdaq-listed) and as a non-executive director of Soleno Therapeutics Inc. (ASND). Previous senior positions in big pharma and biotech include: President, Head of R&D, Avrobio Inc; Head of R&D in Rare Diseases for GlaxoSmithKline; and CMO and SVP of Development at Swedish Orphan Biovitrum AB (Sobi). Her career also includes previous non-executive director positions at Ascendis Pharma, Wilson Therapeutics, TFS International as well as various positions at Amgen Inc., including Executive Development Director of Bone, Neuroscience & Inflammation. Birgitte received her M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.
Job Titles:
- Board Member, Member of Audit Committee
- Partner at Andenæsgruppen
Christian is a partner at Andenæsgruppen. His prior professional experience and past roles include M&A, business development, and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. He is a CFA charter holder, has an MBA from IMD, and holds a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, Christian completed the first two years of law school at the University of Oslo.
Job Titles:
- Deputy Board Member
- Strategic Advisor With Cipriano AS
Einar works as a strategic advisor with Cipriano AS. He was previously a partner of Wikborg Rein & Co and a partner of Arctic Securities ASA. He has held and holds various positions as chairman and board member of both Norwegian and international listed and unlisted companies. He has a Master of Law degree (cand.jur.) from the University of Oslo.
Job Titles:
- Board Member, Chair of R & D Committee
Elaine has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior R&D management teams in Eli Lilly and AstraZeneca. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. Other former positions include co-founder and CEO of Carrick Therapeutics which developed a novel oncology pipeline rapidly transitioning from a preclinical start-up to a clinical stage oncology company. She sits on several international boards for companies in the biotech, services and adjacent areas including Evotec AG. Elaine holds a Ph.D. in Molecular Virology from the University of Edinburgh, Scotland.
Job Titles:
- Board Member, Member of Remuneration Committee
Harald serves as Chief Executive Officer, president and partner of the Datum Group, an investment company based in Oslo, Norway, a position he has held for over 25 years. Datum Group is controlled by Jan Haudemann-Andersen, the largest shareholder of Nykode. Harald holds several board positions in both listed and non-listed companies. In addition, he has held management positions at former Samuel Montague & Co., HSBC, and Handelsbanken, where he served as General Manager, Banking and led the Corporate Finance department in Norway. Mr. Arnet holds a BSBA from the University of Denver, USA, and has completed executive management courses at the London Business School.
Job Titles:
- Chief Financial Officer
- Member of the Senior Management Team
With a long career in the field of finance, Harald joined Nykode Therapeutics in 2021 as CFO. Most recently, he was CFO at Flex LNG, a company owning and operating LNG carriers and listed on both the New York and Oslo Stock Exchanges. Previously, he was CFO in SFL Corporation Limited, a leading international ship-owning company listed on the NYSE. Harald also holds a MSc in Shipping, Trade and Finance from CASS Business School and a MSc in Marine Engineering and Naval Architecture from the Norwegian University of Science and Technology.
Job Titles:
- Chief Development Officer
- Member of the Senior Management Team
Klaus joined Nykode Therapeutics in 2022. He has extensive experience from leading drug development programs within oncology, hematology and infectious diseases in both biotech and pharma companies. His previous roles include Chief Development Officer of CureVac, and Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca and various leadership roles at both GlaxoSmithKline and Genmab. Klaus holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.
Lars Erik Larsson is employed with RASMUSSENGRUPPEN AS, the Company's second-largest shareholder.
Lars Lund-Roland (Chair) is a business and management consultant with background in pharmaceutical marketing and business, including managerial and marketing positions with Merck & Co. Inc., MSD Norway and Bringwell AB. He served on the Board of Nykode from 2014 to 2022.
Lars Lund-Roland was elected at the Annual General Meeting held on May 11, 2023, while Jan Fikkan and Lars Erik Larsson were elected at the Annual General Meeting held on May 12, 2022. Members are elected for two years at a time, unless otherwise has been resolved by the general meeting. The committee members are considered to be independent of the Board of Directors and the Executive Management.
Job Titles:
- Chief Legal Officer
- Member of the Senior Management Team
- Nykode Therapeutics in 2022 As Chief Legal Officer
Louise joined Nykode Therapeutics in 2022 as Chief Legal Officer, bringing over a decade of experience in the life sciences industry from both private and public companies, where in her previous role she has built the global legal department. Louise has a diverse career background in the Biotech, MedTech and Pharma industries. Most recently, she served as VP, Group General Counsel, at KemPharm and Orphazyme. Prior to these roles, she served as Senior Corporate Legal Counsel at Ambu and LEO Pharma, where she held various roles in the law department. Louise holds a law degree (cand.jur.) from the University of Copenhagen in Denmark.
Job Titles:
- Chairman of the Board of Directors, Chair of Remuneration Committee, Member of Audit Committee
From 2007 to end 2010, Martin served as President and Chief Executive Officer of Biovitrum AB and Sobi AB. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc. and was a member of the Senior Executive Committee. He has held and holds various chairman and board member positions in biotech and biopharma companies. Currently he serves as Chairman of Zealand Pharma AS and is a board member of Basilea Pharmaceutica Ltd. Martin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from Uppsala University.
Job Titles:
- Chief Executive Officer
- Member of the Senior Management Team
Michael joined Nykode Therapeutics in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).
Job Titles:
- Chief Scientific Officer
- Member of the Senior Management Team
Mikkel joined Nykode Therapeutics in 2021, bringing extensive experience in drug discovery and development within the areas of oncology, immuno-oncology and infectious diseases. His previous roles include Head of Biologics Drug Design at Servier and CSO of Symphogen, where he has also held the positions VP of Antibody Discovery and Research and Director of Cancer Biology and Immunology. Before that, Mikkel led the receptor tyrosine kinase group at the Department of Radiation Biology, Copenhagen University Hospital. Mikkel holds a Ph.D. from the University of Copenhagen and has authored over 40 peer-reviewed publications.
Job Titles:
- Member of the Senior Management Team
- VP, Head of Quality
Peter joined Nykode Therapeutics in 2021. He is a senior quality manager with broad experience within quality management across GxPs, covering both investigational and commercial products. He has 25 years of experience from the pharma & MedTech industry covering R&D, Product Support and QA/QC. Most recently, he held the role of Head of Global GxP Compliance & Quality Systems in Sobi (Swedish Orphan Biovitrum AB), a global biopharmaceutical company working with rare diseases. Past employments include senior Global QA roles in ALK and Radiometer. Peter holds a MSc in Chemistry and Environmental Biology from Roskilde University in Denmark.
Job Titles:
- Investment Director With RASMUSSENGRUPPEN AS
Trygve is an Investment Director with RASMUSSENGRUPPEN AS, a major shareholder of the Company. Prior to joining RASMUSSENGRUPPEN AS, he worked as an equity analyst with DNB Markets and as product manager with ABB. He has held several Board positions with Norwegian companies. He holds a Ph.D. in Engineering Cybernetics from the Norwegian University of Science and Technology (NTNU).